Clinical Trials Arena: Nova Scotia Health selects Medable’s DCT platform to improve accessibility

Mohammed Ali of Medable: “Reapplying learnings to spark change and achieve scalability”

“The COVID-19 pandemic provided new impetus for creativity in clinical research, following several decades with little major disruption,” says Mohammed Ali, Chief Domain Expert at Medable. “Now we need to persevere to build on this momentum and move forward, applying pandemic learnings to create sustainable approaches.”

‍

What was your background prior to this role, and how did it prepare you for the work you do now? I learned a lot of the key qualities of being a CEO from team sports and my experience conducting research at Stanford. It was the perfect combination that directly applies to leading the team at Medable, with a strong focus on our mission to get effective therapies to patients faster, plus the relentless drive and working as a team to reach our goals.

As the industry moves from a study-by-study DCT implementation approach to a scalable enterprise-wide digital model, DCTs will help drive cycle time reduction and cost efficiencies while supporting the identification of life-changing new compounds.